Belyntic

About:

Novel paradigm-shifting vaccines with emphasis on cellular immunity

Twitter/X: belyntic

Top Investors: HTGF | High-Tech Gruenderfonds, EXIST, Federal Ministry for Economic Affairs and Energy (BMWi), Investitionsbank Berlin, Till Knorr

Description:

Belyntic creates novel vaccines for viral diseases with unmet medical need. We have developed and validated a new platform technology, that generates self-adjuvant synthetic long peptides for a safe and durable induction of cellular immunity.

Total Funding Amount:

3.32M EUR

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Berlin, Berlin, Germany

Founded Date:

2018-05-01

Contact Email:

info(AT)belyntic.com

Founders:

Andreas Regnery, Oliver Reimann

Number of Employees:

1-10

Last Funding Date:

2021-11-08

IPO Status:

Private

Industries: